Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway
Jingfang Zou, Liangli Hong, Chaohuan Luo, Zhi Li, Yuzhang Zhu, Tianliang Huang, Yongneng Zhang, Huier Yuan, Yaqiu Hu, Tengfei Wen, Wanling Zhuang, Bozhi Cai, Xin Zhang, Jiexiong Huang and Jidong Cheng
Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13083
Metformin may exert its anti-proliferative effect on EC cells by activating AMPK and thus decreasing phosphorylation of FOXO1 protein, thereby triggering the relocalization of FOXO1 protein from the cytoplasm to the nucleus and resulting in increased FOXO1 activity. This study provide a novel mechanism of anti-neoplastic effect for metformin through the regulation of FOXO1, and suggest that AMPK-FOXO1 pathway may be a therapeutic target to the development of new anti-neoplastic drugs.